Cancer Treatment Centers of America (CTCA) is now offering the NovoTTF™-100A System (also called NovoTTF Therapy), a device used to treat adult patients with recurrent glioblastoma multiforme (GBM), a form of brain cancer.
What is the NovoTTF-100A System?
The NovoTTF-100A System is a portable, battery-operated medical device that connects to the scalp. It is comprised of two main components:
- An electric field generator (the NovoTTF-100A device)
- 4 INE insulated transducer arrays
How does the NovoTTF-100A System work?
Essentially, the NovoTTF-100A System creates an electric field around the tumor to disrupt the growth and reproduction of cancer cells in the brain.
First, insulated transducer arrays (electrodes) are placed on the scalp using special adhesive material. The transducer arrays deliver low intensity, alternating electrical fields (called tumor treating fields, or “TTFields”) to the brain to disrupt tumor cell division and inhibit tumor growth.
Depending on your treatment plan, your oncologist may have you wear the device for at least 18 hours per day, for at least four weeks. After charging the battery, you may be able to carry the device in a special shoulder bag or backpack for a few hours at a time to receive treatment without disrupting your daily routine.
What are the potential benefits of the NovoTTF-100A System?
The NovoTTF-100A System provides a noninvasive option for patients with a recurrence of GBM for whom treatments like surgery, radiation or cancer drug therapy didn’t work.
The TTFields have been shown to have little effect on normal adult brain cells. And, since the TTFields are only applied to the brain, they do not affect rapidly multiplying cells in the rest of the body.1
The most commonly reported side effect from NovoTTF is a mild-to-moderate scalp rash (beneath the electrodes).
Who is eligible for the NovoTTF-100A System?
The NovoTTF-100A is generally used for patients who have a recurrence of cancer in the brain after receiving chemotherapy, and after surgical and radiation options have been exhausted.
Patients with an active implanted medical device (e.g., a pacemaker), a skull defect (e.g., a missing bone with no replacement) or bullet fragments are not eligible to use NovoTTF-100A.
Where is the NovoTTF-100A System being offered?
CTCA at Eastern Regional Medical Center in Philadelphia and CTCA at Southwestern Regional Medical Center in Tulsa offer the NovoTTF-100A System1, made by NovocureTM.